AI주식인사이트AI Stock Insight
B

일동홀딩스

000230KOSPI의약품 제조업

55.5 / 100

Reference Date: 2026-04-13

Financial Score24.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 6.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Iljung Holdings operates seven business divisions, including pharmaceuticals, advertising, ion water generators, software and medical devices, functional foods, and clinical pharmacology consulting. The company's main revenue comes from pharmaceutical manufacturing and sales (614.94 billion won) and software/medical device development (27.99 billion won), while advertising and ion water generator segments experienced declines compared to the previous year.

Number of Employees

84people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
5.32Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR
0.33Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE
7.20Industry Average 4.425.5Point

1.6x industry avg (good)

Debt Ratio
40.61Industry Average 11.980.0Point

3.4x industry avg (risky)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼3.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲407.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -12.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 9,950Won52-week high 15,81052-week low 5,980
1-month return2.0Point

1m -6.92% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral대표이사(대표집행임원)변경(안내공시)2026-03-26
  • Neutral정기주주총회결과2026-03-26
  • Neutral감사보고서제출2026-03-18
  • Neutral사업보고서 (2025.12)2026-03-18